Vista Pharmaceuticals Limited

VISTAPH6

INE427C01021

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:56 2024-07-16 EDT			5-day change	1st Jan Change
15.48 ^INR	+0.06%		-2.03%	+5.52%

05-28	Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
02-10	Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Vista Pharmaceuticals Appoints N. V. Chalapathi Rao as Whole Time Director

February 11, 2015 at 06:19 am

Vista Pharmaceuticals Ltd. in its board meeting held on February 06, 2015, appointed Mr. N. V. Chalapathi Rao as Whole Time Director of the Company effective February 06, 2015.

Latest news about Vista Pharmaceuticals Limited

Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-28	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-10	CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding	01-07	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-10	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-12	CI
Vista Pharmaceuticals Limited Announces the Resignation of Mr. Nishant Talreja from the Post of Company Secretary, Compliance Officer and Key Managerial Personnel	23-06-16	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-30	CI
Vista Pharmaceuticals Limited Announces Change in Corporate Office Address	23-04-10	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Vista Pharmaceuticals Limited announced that it has received INR 61.895 million in funding	22-12-13	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-15	CI
Vista Pharmaceuticals Appoints Chairman	22-10-20	MT
Vista Pharmaceuticals Limited Announces Executive Changes	22-10-14	CI
Vista Pharmaceuticals Limited Approves Resignation of Narendra Gilaka as Independent Director of the Company	22-09-08	CI
Vista Pharmaceuticals Limited announced that it expects to receive INR 66.895 million in funding	22-09-02	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-13	CI
Vista Pharmaceuticals Limited Announces Resignation of Akash Bhagadia as Company Secretary and Compliance Officer	22-06-27	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-05-30	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-30	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-14	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-13	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-14	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	21-06-30	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter Ended December 31, 2020	21-02-12	CI
Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter Ended September 30, 2020	20-11-12	CI

Chart Vista Pharmaceuticals Limited

Duration

Period

More charts

Vista Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company offers over the counter and prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories. The Company has its United States Food and Drug Administration (USFDA) approved manufacturing facility in India and its marketing and distribution center in United States. Its products include tablet dosage forms and capsule dosage forms. The Company's tablet dosage forms in United States market include sulfamethoxazole & trimethoprim (400/80 mg) and acetaminophen (500 mg) film coated. The Company's tablet dosage forms in Non-United States market include aspirin (300, 325 & 500 mg), atenolol (50 & 100 mg), cotrimoxazole (480 mg), captopril (25 & 50 mg) and frusemide (40 mg). Its capsule dosage forms in Non-United States market include indomethacin (25 mg), piroxicam (10 & 20 mg) and nifedipine (10 mg).

Sector

Pharmaceuticals

Calendar

2024-08-11 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
VISTA PHARMACEUTICALS LIMITED	+5.52%	14.24M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.35B
OTSUKA HOLDINGS CO., LTD.	+38.55%	24.34B
SANDOZ GROUP AG	+27.09%	16.51B
CIPLA LIMITED	+21.19%	14.6B
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.27B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-10.10%	6.57B
ASPEN PHARMACARE HOLDINGS LIMITED	+13.07%	5.76B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals

Vista Pharmaceuticals Limited

Equities

VISTAPH6

INE427C01021

Pharmaceuticals

Vista Pharmaceuticals Appoints N. V. Chalapathi Rao as Whole Time Director

Latest news about Vista Pharmaceuticals Limited

Chart Vista Pharmaceuticals Limited

Company Profile

Income Statement Evolution

Sector Generic Pharmaceuticals